AstraZeneca PLC Announces Lokelma approved in the US for the treatment of adults with hyperkalaemia
Lokelma provides rapid and sustained potassium control for patients in a condition with high unmet need21 May 2018 07:00 BST The US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of adults with hyperkalaemia,1 a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.2 The risk of hyperkalaemia increases significantly for patients with chronic kidney disease (CKD) and for those who take common medications for heart failure (HF),